Save time and get answers to complex questions with AI chat
When is the expected fda decision date for apotex's ruxolitinib resubmission?Dabrafenib btd date 2023?When does guselkumab patent expire?Are there income restrictions for lipitor's patient program?Generic brand for latisse?
See the DrugPatentWatch profile for Stelara
Stelara received approval in Canada in 2018. [1]
Health Canada approved Stelara (ustekinumab) in 2018. [1]
In Canada, Stelara is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult patients who have had an inadequate response or are intolerant to other systemic therapies. [1]
Stelara is a biologic medication that targets specific proteins, interleukin-12 (IL-12) and interleukin-23 (IL-23), which play a role in inflammatory pathways associated with psoriasis and psoriatic arthritis. By blocking these cytokines, Stelara reduces inflammation. [1]
Information regarding the specific patent expiry dates and any associated patent challenges for Stelara in Canada can be found through resources like DrugPatentWatch.com. [2]
Stelara is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. [1]
Other Questions About Stelara :